NECTAR LIFESCIENCES LTD. SHARE PRICE [LIVE]

BSE: INE023H01027   NSE: NECLIFE   SECTOR: Pharma

OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
23.15
Change:
BSE
23.40
Change:
NSE
BSE Click here to view BSE data
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality
Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
Sector
Sensex
Name Mar 21 Dec 20

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in NECTAR LIFESCIENCES LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

NECLIFE News

Frequently Asked Questions

What is the Share price of NECTAR LIFESCIENCES LTD. (NECLIFE)?

NECTAR LIFESCIENCES LTD. (NECLIFE) share price as of August 19, 2022, on NSE is Rs 23.15 (NSE) and Rs 23.40 (BSE) on BSE.

Can I buy NECTAR LIFESCIENCES LTD. (NECLIFE) shares?

Yes, You can buy NECTAR LIFESCIENCES LTD. (NECLIFE) shares by opening a Demat account with Angel One.

How do I buy NECTAR LIFESCIENCES LTD. (NECLIFE) from Angel One?

NECTAR LIFESCIENCES LTD. (NECLIFE) share can be brought through the following modes:
  1. Direct investment: You can buy NECTAR LIFESCIENCES LTD. (NECLIFE) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to NECTAR LIFESCIENCES LTD. (NECLIFE) shares.

In which sector do NECTAR LIFESCIENCES LTD. (NECLIFE) belong?

NECTAR LIFESCIENCES LTD. (NECLIFE) belongs to Pharma.

About NECLIFE

Today's live share price for NECTAR LIFESCIENCES LTD. is NSE: ₹ 23.15, BSE: ₹ 23.40 with a current market capitalization of .

Nectar Lifesciences Ltd is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products. The company manufactures Cephalosporin Active pharmaceutical ingredients, finished dosage forms, Phytochemicals, and hard gelatin capsules at their facilities spread across three Indian states of Punjab, Himachal Pradesh and Jammu. They have developed sustainable production systems to manufacture high quality intermediates and APIs to meet the diverse requirements of their customer base in India and over 45 countries worldwide. The company's business operations are primarily concentrated on manufacturing and marketing of oral and sterile cephalosporins, phytochemicals and allied products. They manufacture and sell a range of cephalosporins and phytochemicals. They are also engaged in contract manufacturing of API's for pharmaceutical players. Nectar Lifesciences Ltd was incorporated on June 27, 1995 as a public limited company with the name Surya Medicare Ltd. The company was established pursuant to a financial collaboration agreement between the Promoters and Punjab State Industrial Development Corporation. In April 1997, the company commenced business with the commercial production of Oral Bulk Drugs at their manufacturing facility located in the B Category zone of Punjab. In March 1998, they started the production of Sterile Bulk Drugs. In the year 1999, they added the formulation facilities by setting up a vial filing section for Crystalline Sterile Bulk Drugs. In the year 2000, the company undertook an expansion by increasing the installed capacity Crystalline Sterile Bulk Drugs from 406 MT to 810 MT. In the year 2001, they also installed one Crystalline section of 65 MT per annum, which commenced production in October 2001. In the year 2002, the company undertook another expansion programme increasing the production capacity for Cephalosporin Sterile. In October 18, 2002, they incorporated Chempharma (Pvt) Ltd as a wholly-owned subsidiary company in Sri Lanka to manufacture API intermediaries. In the year 2003, the company commenced modernization / expansion plan for increasing our presence in the Cephalosporins segment. In April 2003, the company bought back the entire shareholding of PSIDC at a price of Rs 16.47 per share under the One Time Settlement policy announced by Government of Punjab - Industrial Policy, 2003. In the year 2004, the company started production in a portion of the new Cephalosporins plant. In March 26, 2004, the company changed their name from Surya Medicare Ltd to Nectar Lifesciences Ltd. During the year 2006-07, the company commissioned a state-of-the-art facility dedicated to the non-antibiotic therapeutic segment in compliance with stringent US-FDA and EDQM guidelines. The company established a state-of-the-art mint derivatives plant, initiating its business activity into the phytochemicals arena. They also up a menthol flakes facilities at SIDCO Industrial Complex, Jammu to add to the requisite business activity with all the locational benefits to the industry in J&K. They commissioned a unit in Derabassi to process menthol into powder and crystal forms The company also established an Empty Hard Gelatin Capsule unit at Baddi, Himachal Pradesh referred to as Unit VII which commenced production with effect from April 2007. In April 2008, they set up a state-of-the-art facility, Unit X at Derabassi, which commissioned on April 17, 2008. During the year 2008-09, the company increased the production capacity of Bulk Drug & Sterile from 425 MT to 650 MT. Also, they increased the production capacity of Phytochemicals - Menthol from 6000 MT to 7600 MT. They launched 30 formulation brands (P2P). Also, they established a fully-owned formulation R&D centre in Derabassi dedicated to non-cephalosporins related developments like oncology, anti-diabetes, cardiovascular system, female healthcare and anti-HIV. During the year 2009-10, the company increased the production capacity of Bulk Drug & Sterile from 650 MT to 1600 MT. Also, they launched the diagnostic division during the year. In March 2011, the company received approval from the Japanese MOH for their product, Cefuroxime Axetil.

Read more